There hasn't been a new drug approved for lupus in more than
40 years. That may change as the pharmaceutical industry and others invest in identifying promising medicines for lupus and examine their safety and effectiveness through clinical trials.

Visit this page frequently to see the latest on these industry developments.

• Hopeful Testing of Lupus Drug for Multiple Sclerosis
• Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients with Active Systemic Lupus Erythematosus
• A potent treatment for autoimmune diseases
• Newly refined antibody therapy may be potent treatment for autoimmune diseases
• La Jolla Pharma Reports Positive Interim Data From Late-stage Trial Of Riquent To Treat Lupus
• Human Genome Sciences Reports Positive Data From Long Term Treatment With LymphoStat-B(R) In Patients With Active Systemic Lupus Erythematosus
• Anti-CD20 Drugs: Magic Bullet In Treating 'Enigmatic' Lupus?
• Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
• Teva lupus drug fails in clinical trial
• Aspreva Provides Update On Lupus Nephritis Development Program
• Study Reports Epratuzumab Affects B-Cells from Patients With Lupus in a Unique Manner
• La Jolla says in partnership talks on Lupus drug
• Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis
• Aspreva Lupus Drug Fails to Meet Main Goal
• Treatment Provided Improvement In Symptoms In 46 Percent Of Lupus Patients
• Improvement in symptoms in lupus patients at 52 weeks
• Refractory lupus patients remain stable at long term follow-up
• HGS, GSK initiate second phase III trial of lupus drug
• Aspreva says FDA fast-tracks CellCept lupus drug
• La Jolla Pharmaceutical Company Reports Riquent(R) Well Tolerated In Three Studies At International Lupus Congress
• Lupus Meeting News: Is Mycophenolate Mofetil Plus Steroid Now Standard Therapy for Lupus Nephritis?
• Lupus Meeting News: New SLE Treatments Hit B-Cells From Several Directions
• CYC Better Than AZA for Lupus Nephritis; Repeat Renal Biopsy Adds Little Useful Data
• Rituximab Plus Cyclophosphamide May Be an Option for Patients With Refractory Lupus Nephritis
• Cellerant Therapeutics Reversed Autoimmune Disease in Lupus Mice with Transplant of Purified Donor Blood Stem Cells
• MedImmune Publishes New Data in Nature Immunology Demonstrating the Role HMGB1 May Play in Systemic Autoimmune Diseases
• Study: Cyclophosphamide Better Than Azathioprine for Lupus Nephritis
• La Jolla Sees Positive Riquent Results
• HGS, Glaxo Phase III Lupus Trial Underway
• Genes Dictate Response to Lupus Drugs
• On December 18th the FDA warned of safety concerns regarding the treatment of lupus patients with Rituxan.
  People with lupus who have questions or concerns should contact their doctor.
  Press Release: FDA warns of safety concern regarding Rituxan in new patient population
  FDA Public Health Advisory: Life-threatening brain infection in patients with systemic lupus erythematosus after Rituxan (Rituximab) treatment
• Genentech's Next Act
• Drug Market to Treat Systemic Lupus Erythematosus Will Quadruple by 2015
• ImmuPharma Sees Encouraging Results In Phase IIa Lupus Trial
• Aspreva Announces Achievement of Targeted Patient Enrollment in Phase III Clinical Trial for CellCept in Lupus Nephritis
• Drug pipeline suggests glimmer of hope for SLE sufferers

Lupus Drug Development News Archive »

More on Researching Lupus

Weighing Various Lupus Bids: Rituxan A Winner Here, Too?

Connective tissue diseases: evaluation of clinical response

Clinical trial design in systemic lupus erythematosus

B Cells Move to Centre Stage: Novel Opportunities for Autoimmune Disease Treatment

The Autoimmune Disease Database: A Dynamically Compiled Literature-derived Database

The Epigenetic Face of Systemic Lupus Erythematosus

Mice, Humans and Haplotypes--the Hunt for Disease Genes in SLE

Stem Cell Labs Take Private Path

Biotechnology Continues to Break Ground in Autoimmune and Inflammatory Disease Treatment

NIH Budget Cuts May Slow Pace of Research